ArticleEClinicalMedicine2025
A barrier-forming gel for oral mucositis in head and neck cancers patients undergoing radiotherapy: randomized, controlled, multicenter trial.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiotherapy-Associated Pain in Head and Neck Cancer: From Clinical Burden to Neuroimmune Modulator.Journal of clinical medicine · 2026Review
- Bioactive Hydrogels and Scaffolds for Oral Mucosal Regeneration After Oral Squamous Cell Carcinoma Therapy: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Episil is a type of barrier-forming gel. This study was to observe the effects of Episil on oral mucositis (OM) and nutritional status in patients with head and neck cancer (HNC) receiving radiotherapy. Methods: A multicenter and randomized controlled trial included 200 intention-to-treat patients across 7 medical centers in China from February 2022 to June 2024. HNC patients eligible for enrollment were randomly divided into control group and Episil group by 1:1. When the patients developed OM, the control group was gargled with oral gargle solution and the Episil group were sprayed with Episil after using the same gargle intervention. The primary endpoint was incidence of advanced OM, and secondary endpoints were pain relief, nutritional status, overall survival (OS), progression-free survival (PFS), immune function, quality of life (QOL), psychology status and other adverse effects. This trial was registered with Chinese Clinical Trials Registry (URL: https://www.chictr.org.cn/bin/project/edit?pid=136241); accession no: ChiCTR2100055088. Findings: A total of 200 patients were enrolled from 2022 to 2024, including 100 in the control group and 100 in the Episil group. The incidence of Grade III/IV OM in the Episil group was lower than that in the control group (4/100, 4% vs. 14/100, 14%, Interpretation: Episil was shown to delay advanced OM and oral pain in HNC patients undergoing radiotherapy, while improving nutritional status and QOL. Larger prospective multi-national studies are required for further investigation. Funding: This study was funded by the Jilin Province Health Science And Technology ability improvement program (grant numbers: 2024A021), The First Hospital of Jilin University Talent Reserve Program (grant numbers: JDYY-TRP-2024012) and Jilin Province Medical and Health Talents Special Foundation (grant numbers: JLSWSRCZX2023-68 and JLSRCZX2025-042).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.